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ABSTRACT
Introduction: In the last few years, significant advances in molecular biology have provided new therapeutic
options for colorectal cancer (CRC). The development of newdrugs that target the immune response to cancer
cells seems very promising and has already been established for other tumor types. In particular, the use of
immune checkpoint inhibitors seems to be an encouraging immunotherapeutic strategy.
Areas covered: In this review, the authors provide an update of the current evidence related to this
topic, though most immunotherapies are still in early-phase clinical trials for CRC. To understand the
key role of immunotherapy in CRC, the authors discuss the delicate balance between immune-stimulat-
ing and immune-suppressive networks that occur in the tumor microenvironment.
Expert opinion: Modulation of the immune system through checkpoint inhibition is an emerging
approach in CRC therapy. Nevertheless, selection criteria that could enable the identification of patients
who may benefit from these agents are necessary. Furthermore, potential prognostic and predictive
immune biomarkers based on immune and molecular classifications have been proposed. As expected,
additional studies are required to develop biomarkers, effective therapeutic strategies and novel
combinations to overcome immune escape resistance and enhance effector response.
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1. Introduction
Colorectal cancer (CRC) is the third most common cancer
and the fourth leading cause of cancer-related deaths
worldwide in older adults, with a 5-year survival rate that
largely depends on disease stage [1,2].
In the last 15 years, it has been shown that specific gene
alterations have both prognostic and predictive value in CRC
[3,4], with important implications for clinical practice. However,
patients with the same TNM stage often show different clinical
outcomes, reflecting the molecular heterogeneity of this cancer.
More recently, othermolecular features have been elucidated and,
as it has for other solid tumors [5,6], molecular heterogeneity has
also been studied in CRC [7,8].
Interestingly, CRC is currently classified into four consensus
molecular subtypes (CMS) and a fifth unclassified group [9].
CMS1 includes tumors with microsatellite instability (MSI);
CMS2 consists of chromosomal instable (CIN) tumors; CMS3
comprises tumors with KRAS mutations and metabolic dysre-
gulation; and CMS4 includes tumors with a mesenchymal phe-
notype. Among these subtypes, the most immunogenic are
CMS1 and, to a lesser extent, CMS4. Indeed, MSI tumors have
a significantly higher mutational load than other tumor types,
primarily due to a deficient mismatch repair (dMMR) mechan-
ism [10]. This latter feature causes the presentation of many
non-self-antigens and triggers potent immune-response [11].
Despite the immunogenicity of these subtypes, the tumor is
known to establish several mechanisms to escape immune
surveillance [12]. Therefore, different solutions may restore the
immune response against these easily targetable cells. To
restore patient immunity against cancer cells, diverse strategies
may be pursued, including an active immunotherapy (cytokines,
immune checkpoint inhibitors, co-stimulatory pathways and
cancer vaccines) or a passive immunotherapy (adoptive cellular
therapy and monoclonal antibodies) approach [11,13].
Among these strategies, checkpoint inhibition seems promis-
ing, especially for MSI tumors, due to the significant mutational
load and high expression of immune checkpointmolecules, which
cause substantial immunogenicity. In addition to assessing CRC
subtypes and the tumor microenvironment (TME), an immune
score that can predict the outcome of CRC in patients with
tumor infiltrating lymphocytes (TILs) has been proposed [13,14].
The aims of this review are to present the available
knowledge on the underlying molecular features and
immunogenicity of CRC, discuss the role of novel possible
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predictive biomarkers, illustrate the modern immunother-
apeutic approaches and introduce the most relevant
ongoing clinical trials. Although more work is required to
understand the complex interactions between tumor cells
and the immune system, we are at the very beginning of
an exciting revolution. If the promise of these develop-
ments is fulfilled, it could guide clinicians toward a more
‘personalized’ treatment for advanced CRC patients.
2. The role of the immune system in CRC: the tumor
microenvironment and the local immune system
Traditionally, the aggressiveness of a tumor has been defined by
its clinical-pathological characteristics. More recently, advances in
immunology and molecular biology have enabled us to under-
stand the mechanisms underlying the metastatic potential of
tumors. Several studies have increased the knowledge in this
field and clarified the role of the immune system in regulating
cancer growth. Innate immune system cells (macrophages, neu-
trophils, myeloid derived suppressor cells [MSDCs], mast cells,
eosinophils and antigen-presenting cells [APCs]) and adaptive
immune cells (T and B lymphocytes and to a lesser extent NK
cells) [15,16] are among the main ‘characters’. In vitro studies as
well as experimental animalmodels have provided insight into the
complex machinery that functions at the TME level. Preclinical
evidence suggests that abnormal cells without specific antigen
recognition first recruit the innate immune system, and the sub-
sequent inflammatory response is able to promote angiogenesis
and tumor cell growth. Subversion of immune surveillance, orche-
strated by the tumor, involves precise mechanisms developed by
the neoplasm during clonal selection. Notably, the adaptive
immune response requires the recognition of non-self-antigens
by interactions between peptides and the major histocompatibil-
ity complexes (MHCs) of APCs and T cell receptors (TCRs) of CD8+
and CD4 + T cells during antigen presentation [17]. Loss of tumor
antigenicitymay be due to antigens recognized as self as well as to
acquired defects in their presentation. Systematically, a tumor
progresses through three well-defined phases: elimination, equili-
brium and escape (Figure 1). In the first phase (elimination),
immune cells manage to remove high-immunogenicity cells that
express surface proteins that can easily trigger the elimination of
proliferating cells. In the equilibrium phase, some cells clonally
survive due to their ability to hide surface molecules or by inhibit-
ing T cells and macrophages in their ‘tumor clearance process’ via
the expression of co-inhibitorymolecules such as PD-1/2 that bind
B7-H1 on APCs. Similarly, in peripheral lymphoid organs, B7 binds
CTLA-4 on T lymphocytes, subsequently inhibiting them [18,19].
During this phase, a minority population of tumor cells can
develop a high mutational load and stimulate the immune
response, while the majority acquires CIN, which results in abnor-
mal activation of intracellular proliferation, making these cells
Article highlights
● Immunotherapy is a promising therapeutic option in the treatment of
many types of cancer. Currently, many clinical trials are evaluating
the safety, activity, and efficacy of these agents in patients with
colorectal cancer (CRC).
● Increased knowledge of the tumor microenvironment is key to devel-
oping innovative strategies and novel drugs.
● It is essential to identify new potential predictive and prognostic
immune biomarkers that could have a clinical impact on patient
selection and may guide treatment options. In this landscape,
tumor infiltrating lymphocytes (TILs) within human CRC tumors
have a critical impact on patient outcome.
● CMS1, which includes tumors with microsatellite instability (MSI), is
the most immunogenic CRC subgroup. Therefore, patients with CMS1
and TIL-positive tumors could benefit from checkpoint inhibitors.
● Cancer cells may escape immune surveillance and develop resistance
to immunotherapy by acquiring genetic alterations. Consequently,
some patients exhibit primary or acquired resistance.
● There is a complex relationship between immunity, inflammation,
and cancer. Preclinical studies have demonstrated the potential ben-
efit of combining checkpoint inhibitors and anti-COX-2 therapy.
This box summarizes key points contained in the article.
Figure 1. Immunoediting in colorectal cancer.
The figure summarizes the three phases of immunoediting in colorectal cancer, underling the roles of the main effectors in the response of immune
system. Immune cells are able to promote tumor cells killing but have also a series of protumorigenic effects, mainly through host immune-response.
Elimination phase. Immune cells (NK, T-cells and macrophages) manage to remove the neoplastic cells which are so ‘naïve’ to express surface proteins.
Equilibrium phase. Specific subclones are able to survive thanks to their ability to hide antigenic surface molecules or direct ihinibition of t-cells and
macrophagesEscape phase. Several cancer variants escape from the killing process with subsequent evasion and proliferation of resistant clones.
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more likely to escape the immune system [20]. Moreover, extra-
cellular matrix degradation by metalloproteinases and neovascu-
lature produced by abnormal angiogenesis helps circulating tumor
cellsmove tometastatic sites. The ‘seed and soil’ theory posits that
these cells migrate to favorable environments (metastatic sites),
where they enter the extravasation and retention phase, during
which they exert their damaging effects on themetastatic site [12].
2.1 Immune-stimulating network
Immune cells can either destroy or sustain cancer cells. Indeed,
immune cells participate in the physiological repression of
tumor proliferation through a complex network, leading to
tumor eradication or resulting in cancer promotion [21].
Below, we summarize the different cell types involved in
the immune-stimulating network.
2.1.1 CD4+ T cells
The CD3+/CD4+ group of cells represents a family of different
T cells, generally referred as T-helper (Th) cells, which act as
regulators of the inflammatory response directed against for-
eign cells. Among these, CD4+Th1 and CD4+Th17 cells stimu-
late the production and activity of cytotoxic T lymphocytes
(CTLs) by secreting cytokines such as interferon γ (IFN-γ),
tumor necrosis factor α (TNF-α), interleukin (IL)-2 and IL-17
[22–24].
2.1.2 CD8+ T cells
This population of cells is responsible for destroying tumor
cells via direct lysis (CTLs) or producing cytokines that in turn
cause a cytotoxic response. It has been shown in the literature
that a high number of TILs (consisting of activated CD69+ and
cytotoxic CD107a+ cells) characterize earlier stage CRCs
[25,26].
2.1.3 NKT cells
These cells express both a functional T cell receptor (TCR) αβ
and the NK receptor NK1.1. Furthermore, they are able to
interact with glycolipid antigens presented by ‘MHC class-I
like’ CD1d. After stimulation, NKT type I cells promote CTL
and NK cell activation but also have NK-like direct cytolytic
activity. By contrast – as Cardell described in 1995 – the NKT
type II subset plays a role in suppressing CTL- and NK-
mediated tumor lysis as well as in cross-regulating NKT type
I cells. In addition, regulatory T cells (Treg cells or Tregs) have
been demonstrated to reduce the number of NKT type I cells
and thereby down-regulate tumor immunity [27].
2.1.4 NK cells
Classical fully mature NK cells (CD16+ CD57+ KIR+ and LIR+) as
well as memory/adaptive NK cells (CD16+ CD57+ KIR+ LIR+
and NKG2C+) show antibody-dependent cell-mediated cyto-
toxicity (ADCC) and natural cytolytic activity against tumor
cells. In addition, another small subset of NK cells has been
demonstrated to express the inhibitory PD-1 receptor, display
less effective killing activity and favor cancer escape [28].
Dendritic cells (DCs). After internalizing and processing anti-
gens, DCs present functional MHC I- and II-peptide complexes to
naive CD8+ and CD4+ T cells, respectively, to activate a specifically
directed immune response. DC density has also been shown to be
a positive prognostic factor in CRC [29].
2.2 Immune-suppressive network
Immune-suppressive cells in the TME can promote cancer
growth. Below, we describe the cells involved in this network.
2.2.1 CD4+ T cells
CD3+/CD4+ T lymphocytes, the so-called Th2 cells, may
secrete cytokines such as IL-4, IL-5 and IL-10 and inhibit CTL
proliferation. The resulting TME is then enriched by B cells and
Treg cells [30].
2.2.2 CD4+ Treg cells
CD4+/CD25+ Treg cells usually suppress chronic inflammation
and contribute to downregulating the immune response by
producing IL-10 and transforming growth factor β (TGF-β)
[22,31]. In many cancers, pronounced infiltration of FoxP3+
CD4+ Tregs is associated with a worse prognosis, based on the
observation that they can suppress the host immune response
[32,33]. On the other hand, their role in CRC has not been fully
elucidated. Treg tumor infiltration can correlate with a positive
prognosis due to the central role of inflammation in CRC
tumor progression. This process could be slowed down by
the suppressive action of Tregs [34,35].
2.2.3 MSCs (mesenchymal stem cells)
MSCs are non-hematopoietic stromal cells with an extensive
proliferative potential and the ability to differentiate into var-
ious cell types [36]. Notably, MSCs have broad immunosup-
pressive properties with a remarkable role in the TME. Their
immunosuppressive function is elicited by the release of pro-
inflammatory factors. In turn, MSC recruitment through TGF-β
and prostaglandin E2 secretion inhibits lymphocyte prolifera-
tion and DC maturation by the downregulation of MHC and
co-stimulatory molecules expression [37]. They promote the
production of tolerogenic DCs, M2 macrophages and Treg
cells. The main factors involved in this signaling are plasmino-
gen activator inhibitor 1, IL-6, neuregulin 1, human epidermal
growth factor receptor 2/3, phosphatidylinositol-4,5-bispho-
sphate 3-kinase and the AKT signaling pathway [38]. MSCs
function in tumor development and immune surveillance eva-
sion by encouraging the emergence of resistant clones
through selective pressure and subsequent evasion and
rapid proliferation. The stromal cell compartment has an
important prognostic relevance to CRC patient outcomes.
MSCs in the colon TME employ many pathways that result in
tumor initiation, angiogenesis, resistance to chemotherapy,
invasion and metastasis [36,39].
2.2.4 CAFs (cancer-associated fibroblasts)
Among the stroma players, CAFs have a critical role in CRC
immunosuppression. As a result, they may strongly pro-
mote tumor progression, epithelial mesenchymal transi-
tion, and metastasis through TGF-β/SMAD signaling [40].
High levels of CAFs are correlated with poor prognosis in
CRC [41].
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2.2.5 MDSCs
These cells arise from different myeloid-derived cells at
various stages of differentiation. They are able to enhance
immune suppression by acting both on the innate and
adaptive immune system. They are involved in tumor
development and progression through the release of
immunosuppressive molecular mediators such as NOS,
TGF-β, IL-10, and PGE2 [38]. A study of 64 patients with
CRC indicated that these patients had a high absolute
blood count of MDSCs compared with negative control
individuals; similarly, patients with high levels of MDSCs
had a more advanced stage of the disease [42].
2.2.6 Mast cells
Mast cells also play an important role in the immunosuppres-
sive cross talk: they interact with MDSCs via the CD40/CD40L
axis, releasing cytokines and chemotactic factors and enhan-
cing both the number and activity of MDSCs in the TME [43].
2.2.7 Macrophages
Macrophages are cells that clear neoplastic cells through pha-
gocytosis. They also release matrix-degrading substances
called metalloproteinases and cysteine cathepsin proteases
with the same function. This mechanism facilitates tumor
invasion of the stromal compartment, which allows the neo-
plasm to spread through the organism [44].
Pro-inflammatory or anti-inflammatory signals may activate
macrophages. M1 macrophages act as effector cells in Th1
responses through the release of IL-1β, TNF-α, IL-12, IL-23,
reactive oxygen species (ROS) and nitric oxide (NO), thus kill-
ing tumor cells. Conversely, M2 macrophages are involved in
tumor growth and metastasis [45,46]. They inhibit the genera-
tion of M1 macrophages and block immune surveillance by
expressing arginase 1 and secreting cytokines such as IL-1, IL-
6, TGF-β, and IL-10. Notably, tumor associated macrophages
(TAMs) display an M2-like phenotype. In turn, they recruit
immunosuppressive cells by secreting cytokines that differ-
entiate lymphocytes into Th17 cells (IL-23, IL-6, IL-1β, TGF-β)
or Tregs (TGF-β, IL-10) [38,47,48]. High levels of metalloprotei-
nase-9 and M2 cells have been found to be independent
predictors of metastasis and of poor outcome in CRC [41,44].
Furthermore, TAMs can induce resistance to 5-fluorouracil (5-
FU)-based chemotherapy. This fluoropyrimidine triggers the
p-JNK/caspase-3 pathway, inducing cell death, but also stimu-
lates the production of putrescine in macrophages through
ornithine decarboxylase (ODC), inducing chemoresistance [49].
Fusobacterium nucleatum: Evidence has recently shown that
this bacterium contributes to CRC development. Particularly,
some studies have demonstrated that fusobacterium could
accelerate tumorigenesis in mice. This is primarily due to
MDSC recruitment and expansion, resulting in immunosuppres-
sion and immune escape. Moreover, a correlation between
MDSCs, TAMs, DCs and Fusobacterium was reported.
Remarkably, an up-regulation of PTGS2 (COX-2), IL-1β, Il-6, IL-8,
TNF (TNF-α) and MMP3 was noted, suggesting an NF-κB-driven
pro-inflammatory response [50]. In a recent study, F. nucleatum
was detected in 13% of CRC tissues. Patients without F. nucle-
atum showed a higher density of CD3+ T cells compared to
patients with F. nucleatum (multivariable odds ratio, .47; 95% CI
.26–.87; Ptrend = .006). However, a significant association
between the presence of F. nucleatum and CD8+, CD45RO+, or
FOXP3+ T cells (Ptrend > .013) was not observed [51].
3. How to select patients who are likely to benefit
from immunotherapy
Increasing insights have established the pivotal role of the
immune system in cancer growth control. More specifically,
immunological manipulation has led to the development of
new agents that unleash the immune system against cancer.
Indeed, in this era, immunotherapy represents a promising
option for the treatment of an increasing number of malig-
nancies, including CRC. Unfortunately, only some CRC patients
seem to benefit from immunotherapy. By investigating poten-
tial prognostic and predictive immune biomarkers, we may be
able to identify patients who would benefit from these new
strategies [52].
Though this may be difficult at first, it is essential to clarify the
role of both the immune and molecular classifications of CRC.
3.1 Immune classification: immunoscore
For more than 10 years, TILs, defined as CD3+ and CD45RO+
cells within the tumor [53], have been known to have a critical
impact on patient outcome [54]. In particular, the observation
that CRC patients with a high infiltration of memory T cells
and CD8+ T cells experienced a longer progression free survi-
val (PFS) and overall survival (OS) [55] led to the proposal of an
immunoscore classification [54].
The immunoscore is obtained by counting two lymphocyte
populations identified by CD3/CD45RO, CD3/CD8 or CD8/
CD45RO positivity, in both the tumor core (TC) and invasive
margin (IM). Evaluating both tumor regions (TC and IM)
increases the accuracy of survival prediction. The immuno-
score, which ranges from a score of 0 (a low density of both
cells in both cancer regions) to a score of 4 (high density), may
predict disease free survival (DFS) and OS in CRC [56] and may
help identify patients with early-stage disease who might
potentially benefit from adjuvant chemotherapy [57].
3.2 Molecular subtype classifications
CRC is classified as four CMS subgroups and a fifth residual
unclassified group (13%) [9]. CMS1 (MSI-like, 14%) includes
MSI tumors; CMS2 (canonical, 37%) consists of CIN tumors
with epithelial differentiation and a strong upregulation of
WNT and MYC downstream targets; CMS3 (metabolic, 13%)
encompasses tumors with KRAS mutations and metabolic
dysregulation; and CMS4 (mesenchymal, 23%) includes tumors
with a mesenchymal phenotype. Only two of these subgroups
showed high expression of immune signatures: CMS1 and
CMS4. More specifically, CMS1 encompasses tumors with
deviations (expansion or contraction) in microsatellite regions,
defined as MSI. The cause of this alteration is dMMR enzymes,
with an increased mutational rate (genomic instability) result-
ing from mutations in DNA MMR genes (i.e. MLH1, MSH2,
MSH6 and PMS2) [58,59]. A high frequency of MSI in CRC has
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been revealed to be an independent prognostic factor for
favorable outcome and reduced metastatic spread in early
stages of the disease [60]. More recently, some studies, evalu-
ating the polymerase genes POLE and POLD1in MSI-high
tumors, have identified a hypermutated phenotype with up
to more than 1,000,000 base substitutions per tumor when
these genes are mutated. Notably, MSI-high tumors have a
mutational rate 20 times higher than MSS tumors, reflecting
the tendency to express a higher load of neo-antigens, thus
improving the response to immunotherapy [61].
CMS1 also includes tumors with methylated CpG islands
(CpG island methylator phenotype, CIMP-H), which often
results in gene silencing, and tumors with mutations in the
BRAF oncogene [9,61,62]. Interestingly, this subgroup displays
a diffuse immune infiltrate. Moreover, this subtype exhibits
high expression of T cell-recruiting chemokines as well as the
expression of Th1 cytokines that have been shown to correlate
with good prognosis in CRC [55]. Indeed, dMMR causes a high
mutational oncogenic load, such as frameshift mutations and
neo-antigen expression, which can induce an active immune
microenvironment reaction characterized by a high density of
TILs [63]. Further investigations have explored the association
between neo-antigens and immune infiltrate in CRC. A higher
neo-antigen load was shown to be associated with a high
lymphocyte score (Spearman’s rank correlation coefficient = .29,
p value = 2.6X10−11) and with increased CRC-specific survival
(log rank test, p value = .004; multivariate HR = .57 [95% CI,
.35–.93], p value = .03) [64]. Therefore, tumors with a high neo-
antigen load would seem to benefit more from immunother-
apy [61].
Conversely, CMS4 includes tumors with a mesenchymal phe-
notype characterized by TGF-β activation, stromal invasion, and
angiogenesis. This subgroup displays high expression of mye-
loid chemokines, angiogenic factors, immunosuppressive
factors and complement components, which correlate with
worse prognosis in CRC.
Interestingly, the genes (CD274 and PDCD1LG2) encoding
the PD-1 ligands are highly expressed in CSM1 tumors and in
some tumors of CSM4 [55].
3.3 Integrating immune and molecular classification:
individualization of potential prognostic and predictive
factors
A recent analysis of 270 patients from The Cancer Genome
Atlas (TCGA) found that MSI cancers have higher intratumoral
immune gene expression in all immune subpopulations and
higher immunoscores than MSS tumors [14,65]. These data
support the treatment of MSI-like CRC patients with anti PD-
1/PD-L1. Indeed, a recent clinical trial showed that MSI
patients responded to PD-1 blockade [66]. Le’s study, testing
pembrolizumab (anti-PD-1), as well as data recently presented
at ASCO 2016 regarding the combination of nivolumab (anti-
PD-1) and ipilimumab (anti-CTLA-4) in CRC patients with either
MSI or MSS tumors confirmed that the optimal candidates for
anti-PD-1 or anti-PD-L1 therapy are those with MSI tumors
[67]. The response to PD-1/PDL-1 blockade might not be the
same in all MSI CRC patients. Indeed, only one-third of MSI
CRC patients can benefit from immunotherapy, and the dura-
tion of response is not homogeneous [68]. Although this study
provides novel insights into the pathological and molecular
bases of PD-L1 expression in CRC, important questions remain
with respect to genetic or epigenetic alterations that could
critically affect PD-L1 expression in CRC. The different
responses to anti-PD-1/PD-L1 therapy of MSI CRCs with PD-
L1 positivity in tumor cells or in immune cells should also be
considered.
Moreover, some evidence has shown that a high density of
MDSCs is associated with a poor prognosis in many tumors.
Interestingly, granulocyte MDSCs that expressed higher levels
of PD-L1 induce robust immunosuppressive activity in meta-
static CRC (mCRC). MDSC levels are apparently higher in the
blood of patients with mCRC rather than in healthy subjects.
Moreover, a high level of granulocyte MDSCs is associated
with worse prognosis, and reduced blood levels of granulo-
cyte MDSCs after treatment with 5-FU, oxaliplatin and bevaci-
zumab seemed to be associated with a longer median PFS
[42]. Certainly, further studies are needed to confirm if granu-
locyte MSDC density is an independent prognostic factor in
mCRC.
In conclusion, the combination of different biomarkers (i.e.
properly defined and documented PD-L1 expression, the pre-
sence of TILs, and molecular classification) may help identify
responders to immunotherapy among MSS patients and non-
responders among MSI patients (Figure 2).
Notably, current evidence has suggested that patients with
CRC tumors that exhibit the presence of TILs, MSI-H and high
expression of neo-antigens are good candidates for check-
point immunotherapy [61,69]. Like CMS1 tumors, CMS4
tumors also exhibit immune, inflammatory and immunosup-
pressive cells, indicating that immunotherapy could also be
applied to cohorts of patients with a mesenchymal CRC phe-
notype [55].
However, there is no universal consensus regarding the use
of PD-1 and PD-L1 expression in CRC treatment decisions. This
lack of uniformity is due to heterogeneity in the testing meth-
odology and to the variable expression of the latter; therefore,
more studies are required to validate the use of PD-1 and PD-
L1 as predictive biomarkers. Furthermore, some studies have
demonstrated that PD-L1 expression is inversely associated
with MSI-H status as well as FOXP3+ cell density [70].
4. Clinical trials of mCRC immunotherapies
While immunotherapies are being developed for different
cancer types, many trials are currently recruiting patients to
explore the safety, activity and efficacy of these new agents
for mCRC.
Ipilimumab is one of the first drugs designed to interfere
with an immune checkpoint. Ipilimumab is a fully human
monoclonal antibody (IgG1) that blocks CTLA-4 to promote
antitumor immunity, and it has extended survival in patients
with advanced melanoma [71]. Novel promising monoclonal
antibodies that target other checkpoints such as PD-1 (e.g.
pembrolizumab, nivolumab) or PD-L1 (e.g. atezolizumab) can
boost the immune response against cancer cells. These drugs
are now being tested in clinical trials either alone or in
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combination. However, many of these mCRC trials are
ongoing, and only a few mature results have been obtained.
The ESMO consensus guidelines [72] recommend MSI test-
ing because of its strong predictive value for the use of
checkpoint inhibitors in the treatment of CRC patients, sug-
gesting the potential use of pembrolizumab in patients with
dMMR tumors. According to reports from a small phase II trial,
the immune-related objective response rate (ORR) and
immune-related 6-month PFS rate were 40% and 78%, respec-
tively, for the 11 CRC patients with dMMR and 0% and 11% for
the 21 CRC patients with proficient MMR (pMMR). This result
supports the hypothesis that MMR status could predict the
efficacy of immunotherapy [73].
Based on promising results published by Le [73], in the
phase III KEYNOTE-177 trial [74], patients with MSI-high (MSI-
H) or dMMR advanced CRC will be randomly assigned to
receive either pembrolizumab or an investigator’s choice che-
motherapy regimen among six different choices for the
upfront treatment of advanced CRC. The primary trial end-
point is PFS, and the results are expected in 2019. Another
phase III trial [75] is comparing regorafenib [76] to cobimetinib
(MEK inhibitor) plus atezolizumab or to atezolizumab mono-
therapy in pretreated CRC patients. Cobimetinib promotes
MHC I expression, inducing the accumulation of intratumoral
CD8 T cells and thereby sensitizing tumors to atezolizumab.
The rationale for the combination derives from preclinical
models showing that cobimetinib favors PD-L1 upregulation
and accordingly enhances anti-PD-L1 activity in serial biopsies
taken from patients included in a phase Ib trial. The results of
the phase Ib trial [77] were presented at the 2016 ASCO
Meeting and then at ESMO 2016. The study included three
patients with mCRC (two KRAS mutant, one KRAS WT) in the
dose escalation cohort and 20 (all KRAS mutant) in the dose
expansion cohort. The combination was well tolerated, and
only 9% of patients had treatment-related serious adverse
events (nausea/vomiting and cerebrovascular accident). The
ORR was 17% (four partial response, five stable disease), with
the duration ranging from 5.4 to 11.1 months. Activity did not
correlate with PD-L1 expression. Interestingly, three of the
responders were pMMR. These results showed that even
patients with MSS CRC are likely to respond to the combina-
tion of cobimetinib and atezolizumab, paving the way for the
ongoing phase III trial. This trial is recruiting patients with
histologically confirmed CRC who have experienced disease
progression on at least two systemic chemotherapy regimens
for mCRC. Only MSI-stable patients will be eligible, and the
primary endpoint is OS.
Finally, the IMPALA trial is testing MGN1703 as switch
maintenance therapy in patients with mCRC who achieved a
partial response after first-line standard chemotherapy.
MGN1703 is a DNA-based Toll-like receptor (TLR) agonist that
acts as an immunomodulator and showed promising activity
in the IMPACT phase II trial when compared to placebo [78].
The study requires no molecular selection.
The results of an interim analysis of CheckMate-142 [67], an
international phase II, open-label, noncomparative trial enrol-
ling patients regardless of their MSI status, were recently pre-
sented [67]. MSI-H CRC patients received nivolumab (n = 70)
or 3 mg/kg nivolumab plus 1 mg/kg ipilimumab (n = 30) for
four doses followed by 3 mg/kg nivolumab every 2 weeks until
unacceptable toxicity or disease progression. The primary end-
point was investigator-assessed ORR in MSI-H patients. The
investigator-assessed ORR for MSI-H patients receiving 3 mg/
kg nivolumab with at least 12 weeks of follow up was 25.5%
and 33.3% for the combination arm. The six-month PFS rate
was 45.9% (95%CI: 29.8–60.7) and 66.6% (95% CI: 45.5–81.1)
for nivolumab and nivolumab plus ipilimumab, respectively.
The six-month OS rate was 75% (95% CI: 58.5–85.7) and 85.1%
(95% CI: 65.0–94.2) respectively.
Therapeutic vaccines, adoptive cell therapy, oncolytic virus
therapy and cytokines are also under investigation. Most of
these immunotherapies are still in early-phase clinical testing,
Figure 2. Immunoscore, gene profile, tumor location and prognosis in colorectal cancer.
The figure summarizes the overlapping of immune and molecular classification and differences in clinical presentation and prognosis. A high immunoscore is more
frequent in right side MSI tumors and is correlated with good prognosis. On the other hand, left side MSS tumors commonly show a low immunoscore and worse
prognosis.
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but their activity results in other cancer types suggest testing
them in CRC as well. Table 1 summarizes key clinical trials that
are now evaluating the activity/efficacy of different immu-
notherapeutic agents in mCRC.
5. Looking ahead
Immunotherapy is a promising treatment option for many
cancer patients. Specifically, the advent of ipilimumab, nivolu-
mab and pembrolizumab in clinical practice has markedly
improved the outcomes of these patients with durable
responses and significant survival benefits. Unfortunately,
patients do not all equally benefit from this new strategy. To
understand the reasons for the heterogeneity of the
responses, we should first consider the potential mechanisms
of primary and acquired resistance to immunotherapy and
then attempt to understand how to enhance the benefit of
this therapeutic approach.
5.1 Immunotherapy: how do tumor cells acquire
resistance?
Tumor cells may escape immune surveillance by acquiring
different genetic alterations. Indeed, some patients exhibit
an innate resistance to immunotherapy. A higher expression
of mesenchymal transition genes (AXL, ROR2, WNT5A, LOXL2,
TWIST2, TAGLN, and FAP), immunosuppressive genes (IL10,
VEGFA, and VEGFC) and chemokines that recruit immunosup-
pressive cells (CCL2, CCL7, CCL8, and CCL13) may be asso-
ciated with innate anti-PD-1 resistance.
A recent study [80] used an innate anti-PD-1 resistance
signature (IPRES) to evaluate mesenchymal transition, angio-
genesis, hypoxia and wound healing in metastatic melanoma.
IPRES-enriched tumors were associated with anti-PD-1 nonre-
sponding cancer (OR = 4.6; p = .013), while IPRES-low tumors
were associated with anti-PD-1 responding cancer (OR = .15;
p = .04). Conversely, the IPRES signature showed no similar
association in the context of anti-CTLA-4.
By contrast, some patients quickly develop resistance, even
after an initial benefit with a significant reduction in tumor
burden, suggesting that a rapidly proliferating resistant clone
may cause the progression of resistance. Interestingly, Ribas
et al. identified acquired mutations in four patients treated
with pembrolizumab at disease progression through whole-
exome sequencing. They showed that two out of the four
patients presented a loss-of-function mutation in the IFN recep-
tor pathway, specifically involving Janus kinase-1 (JAK-1) and
JAK-2. Moreover, in a third patient, the resistance was due to a
truncating mutation of beta-2-microglobulin (B2M), an essential
component of the MHC-I structure, which is necessary for anti-
gen binding and presentation. As a result, these mutations
cause decreased antigen presentation and immune escape [81].
Likewise, high tumor PGE2 expression represents a key
mediator of immune resistance, mainly due to the secretion
of suppressive chemokines and the recruitment of gMDSCs,
which results in immunogenic loss [82].
5.2 Immunotherapy effect: how can it be enhanced?
Following the reports of positive data obtained in melanoma,
renal tumors and lung cancer, the use of immunotherapy to
treat many other cancer types, including gastrointestinal
malignancies, has attracted interest. Ongoing research efforts
are aimed at identifying new targets and developing novel
approaches to enhance immunotherapy [83]. More specifically,
immunotherapy alone appears to have modest success, likely
due to the complexity of the TME. Therefore, recent trials have
been evaluating novel combined approaches, such as
immune-chemotherapy or combo immunotherapy, that
could be more effective than chemotherapy or immunother-
apy alone [67,84,85].
Moreover, some authors observed that VEGF-A blockade
could help sensitize T cells to anti-PD-1 treatment and that
high VEGF-A levels may be involved in resistance to this
treatment [86]. Therefore, these data suggest a potential ratio-
nale for the association between anti-angiogenic molecules
and checkpoint inhibitors, with particular interest for VEGF-A-
producing tumors. It will be interesting to verify if combining
immunotherapy with chemotherapy and/or biological thera-
pies (anti-EGFR or anti-VEGF) could produce a synergistic
effect in CRC (Table 1). Obviously, many clinical trials are
required to evaluate the efficacy and safety of these novel
approaches.
It would also be useful to understand how to enhance
immunotherapy, increasing the effector response and redu-
cing the inflammatory component. Indeed, tumor cells can
exploit inflammation for cancer promotion. COX-2 deregula-
tion plays a pivotal role in tumor cells. Unlike COX-1, which
is expressed constitutively in most cells, COX-2 is produced
in response to growth factors and cytokines [87,88]. Once
synthesized, prostaglandin-2 (PGE-2) acts in an autocrine
and paracrine manner though four receptors to direct
epithelial-mesenchymal transition, angiogenesis, HIF-1 tran-
scription, acid oxidation production, chemo-resistance, M2
polarization, and Treg and MDSC recruitment. Furthermore,
a cross talk between the immunosuppressive microenviron-
ment and the EGFR pathway activates several signal trans-
duction cascades, including the MAPK, AKT, and PI3K
pathways, and subsequent tumor growth and immunosup-
pression [89].
Preclinical studies [82,90,91] found that COX inhibition could
enhance the efficacy of anti-PD-1 blockade. Zelenay and collea-
gues [91] inoculated Ptgs2-deficient and BRAFV600E mutated
cells in WT mice and found that the loss of COX-2 expression
leads to a significant decrease in immunosuppressive cytokine
(IL-6) and chemokine (CXCL1) expression and a simultaneous
marked increase in immune-stimulating factors (IFN-g, T-bet,
CXCL10, IL-12 and IFN-I) and co-stimulatory molecules. Unlike in
COX-deficient tumors, DCs are absent in COX-competent
tumors. More interestingly, in the same study, mice were ran-
domly assigned to receive aspirin, celecoxib, or anti-PD-1 in
monotherapy or the combination of a COX inhibitor plus anti-
PD-1. As expected, the combination promoted a much more
rapid tumor regression, with the eradication of BRAFV600E
melanoma cells. This suggests that the association of COX
inhibitors and immune checkpoint blockers could enhance
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the efficacy of immunotherapy and prevent resistance
development.
6. Conclusion
In recent years, several therapeutic approaches have
reshaped the overall strategy of treating CRC patients
and have markedly improved patient survival.
Significantly, emerging novel immunotherapeutic
approaches could change the CRC landscape. Moreover,
selection criteria are necessary to identify patients who
may benefit from immune checkpoint inhibitors. To this
end, the presence of TILs is one of the most important
predictors. Through the immunoscore determined by the
quantification of two lymphocyte populations in both the
core and the invasive margin of the tumor, CRC has been
classified into four different subgroups. Two of these, the
first consisting of MSI tumors and the other one including
tumors with a mesenchymal phenotype, seem to be appro-
priate subgroups for PD-1 inhibitor immunotherapy. DNA
MMR and MSI status is now clinically significant to deter-
mining whether patients may be eligible for immunother-
apy in clinical trials, but we ignore the potential predictive
factors in MSS patients. To date, the predictive role of the
differential expression of PD-1 and PD-L1 has not been
completely clarified, although some evidence suggests
that high expression correlates with a better immunother-
apy efficacy. Currently, most immunotherapies are still in
early-phase clinical testing for CRC, but their successful use
in other types of cancers suggests that they may ultimately
prove useful for CRC as well. As the field of immunother-
apy treatment continues to evolve, a more comprehensive
knowledge of resistance mechanisms will be mandatory,
which will lead to the development of novel strategies to
overcome both primary and acquired resistance to anti-PD/
PDL-1 antibodies.
7. Expert opinion
Since the first presentation in 2010 of ipilimumab data in
melanoma, checkpoint immunotherapy has revolutionized
the treatment of cancer. This strategy later succeeded in
other diseases, such as renal cell carcinoma and non-small
cell lung cancer. Despite a strong rationale for adopting
the same strategy in CRC, first clinical data only became
available in 2015, and the clinical development of check-
point inhibitors in this field is still in an early phase. This
did not occur by chance. In fact, CRC has received less
attention than other cancers in the field of humoral immu-
notherapy primarily because of the lack of CRC patients
who respond to this treatment. As far as we know, only
MSI-H CRC tumors respond to checkpoint inhibition. In this
review, we explained the basis for this and the results
obtained thus so far. This apparent limitation could be
seen as a point of strength. Each time a new drug is
added to the list of approved agents in oncology, the
scientific community claims to have powerful and ready-
to-use predictive markers, which is what we have with
microsatellite status and checkpoint inhibitors in CRC.
Though the only available data have come from phase II
trials, as phase III trials are currently ongoing, the results
achieved so far are exciting [67,73]. Based on these results,
the Food and Drug Administration (FDA) has granted
Breakthrough Therapy Designation to pembrolizumab for the
treatment of MSI-H CRC. This paves the way for new thera-
peutic possibilities but also raises new doubts and questions,
some of which concern very practical matters.
The first is ‘positioning’. Impressive data regarding immune
checkpoint inhibitors in CRC have been reported, but stage IV
CRC is not curable in 90% of cases by definition. Should we
use checkpoint inhibitors in all mCRC patients as a first
approach, or is it more prudent to wait for head-to-head trials
comparing immunotherapy to the standard of care? Using
these agents in the treatment of stage IV radically resected
patients or as adjuvant therapies is even more challenging.
Certainly, drug labels will help determine how we use these
agents, but we can easily anticipate that medical oncologists
will have to balance economic limitations and the best inter-
ests of their patients.
The second is ‘response assessment’. Traditionally,
tumor response assessment is based on the RECIST criteria.
These criteria are applicable to chemotherapeutic agents,
due to their cytotoxic action. Drugs with different mechan-
isms of action require different response evaluation cri-
teria. This problem has already been encountered in CRC
treatment with anti-angiogenic agents, and a definitive
solution has not yet been found. The different mode of
antitumor action of immunotherapy requires modified
tumor response criteria (irRC) that consider new phenom-
ena such as pseudoprogression [92]. Much work needs to
be done in this field in the very near future.
The third is ‘tolerability’. Immune checkpoint inhibitors
have been shown to have a different toxicity profile com-
pared with traditional chemotherapy and targeted agents
[93]. The first results have been reassuring and have not
noted specific concerns for CRC patients. Nevertheless, the
number of patients that have been treated up to this point
is quite limited, and the follow-up times are rather short.
We cannot forget that preliminary efficacy results suggest
that many patients are candidates to receive the treatment
for years. What about immune-related colitis and intestinal
resections? What about the coexistence of inflammatory
bowel disease?
Other important questions concern the direction of future
clinical research:
- Is MSI the only biomarker? Are there other potential
candidate molecular predictors of response? Beyond dMMR
tumors, another subset of hypermutated CRCs, such as
those bearing somatic or germ line mutations in the DNA
polymerase E (POLE) gene, has been described [94]. This is
a small subgroup of patients, approximately 0.5–2% of
patients with mCRC, but these patients may have a strong
biological basis for checkpoint inhibitor sensitivity [94].
- Is there any difference between different checkpoint inhibi-
tors (i.e. nivolumab vs pembrolizumab)? Is there a real benefit in
combining the anti-CTLA-4 ipilimumab with nivolumab? What
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about the treatment duration in patients undergoing a complete
response or post-progression treatment for those who acquire
resistance to immune checkpoint inhibitors?
- What about the other tumor types? Is there anything we can
do to ‘ignite a cold tumor’, to sensitize the vast majority of CRC
patients, who are affected by MSS cancers [95], to checkpoint
inhibitors? Combination therapies to increase tumor sensitivity
to immunotherapy are under investigation. The rationale for com-
bining a MEK inhibitor such as cobimetinib with an antibody
directed against PD-L1 such as atezolizumab is described above
[77]. A more ‘dirty’ option may be combining immune checkpoint
inhibitors with systemic therapies (i.e. chemotherapy or targeted
therapy) or local treatments (i.e. radiation therapy) to exploit the
immunogenic release of antigens from cancer cells. Innovative
approaches under discussion include pretreating the tumor with
alkylating mutagenic agents, such as temozolomide [96,97], fol-
lowed by immune checkpoint inhibitors alone or in combination.
- Is there any ‘alternative’ immunotherapy? Immune check-
point inhibition is not the only immunotherapy option,
although this is the first successful approach. Alternative stra-
tegies currently under investigation include vaccines, cytokine
therapy, TLR agonists, and adaptive cell therapy. In CRC, some
of these efforts have failed in the past. However, the present
level of knowledge and technology makes success more likely.
Most of the studies are still in early phase I and II trials, but
results from phase III studies, such as the IMPALA (testing the
TLR9 agonist MGN1703) are awaited in the near future [96].
In conclusion, even though novelty always brings concerns
and new challenges, we are excited for the potential to treat
some CRC patients with checkpoint inhibitors and for the
opportunities that immunotherapy will likely provide.
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